CN110317259A - 表皮生长因子受体表面抗原的表位及其用途 - Google Patents

表皮生长因子受体表面抗原的表位及其用途 Download PDF

Info

Publication number
CN110317259A
CN110317259A CN201910572748.1A CN201910572748A CN110317259A CN 110317259 A CN110317259 A CN 110317259A CN 201910572748 A CN201910572748 A CN 201910572748A CN 110317259 A CN110317259 A CN 110317259A
Authority
CN
China
Prior art keywords
amino acid
acid sequence
seq
epitope
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910572748.1A
Other languages
English (en)
Chinese (zh)
Inventor
金世镐
洪广元
张基奂
金敏洙
李美祯
元钟和
许旻奎
曹炫寿
俞知镐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ryokugugi K K
Mogam Institute for Biomedical Research
Original Assignee
Ryokugugi K K
Mogam Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ryokugugi K K, Mogam Institute for Biomedical Research filed Critical Ryokugugi K K
Publication of CN110317259A publication Critical patent/CN110317259A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001131—Epidermal growth factor [EGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
CN201910572748.1A 2012-03-27 2013-03-27 表皮生长因子受体表面抗原的表位及其用途 Pending CN110317259A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616073P 2012-03-27 2012-03-27
US61/616,073 2012-03-27
CN201380022281.4A CN104394879A (zh) 2012-03-27 2013-03-27 表皮生长因子受体表面抗原的表位及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380022281.4A Division CN104394879A (zh) 2012-03-27 2013-03-27 表皮生长因子受体表面抗原的表位及其用途

Publications (1)

Publication Number Publication Date
CN110317259A true CN110317259A (zh) 2019-10-11

Family

ID=49260689

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910572748.1A Pending CN110317259A (zh) 2012-03-27 2013-03-27 表皮生长因子受体表面抗原的表位及其用途
CN201380022281.4A Pending CN104394879A (zh) 2012-03-27 2013-03-27 表皮生长因子受体表面抗原的表位及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380022281.4A Pending CN104394879A (zh) 2012-03-27 2013-03-27 表皮生长因子受体表面抗原的表位及其用途

Country Status (16)

Country Link
US (3) US20150231220A1 (https=)
EP (1) EP2832363B1 (https=)
JP (1) JP6209206B2 (https=)
KR (1) KR101930019B1 (https=)
CN (2) CN110317259A (https=)
BR (1) BR112014024192A2 (https=)
CA (1) CA2871111C (https=)
CO (1) CO7160042A2 (https=)
DK (1) DK2832363T3 (https=)
ES (1) ES2694679T3 (https=)
IN (1) IN2014DN08778A (https=)
MX (1) MX356550B (https=)
MY (1) MY168077A (https=)
PH (1) PH12014502360B1 (https=)
RU (1) RU2650770C2 (https=)
WO (1) WO2013147509A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10759836B2 (en) 2014-07-18 2020-09-01 University Of Washington Cancer vaccine compositions and methods of use thereof
KR101776879B1 (ko) * 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
CN115226700A (zh) * 2022-08-02 2022-10-25 江苏克诺克智能科技有限公司 一种粮面害虫诱捕器及诱捕系统

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459061A (en) * 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
CN1432063A (zh) * 2000-05-19 2003-07-23 梨树化学株式会社 抗表皮生长因子受体的人源化抗体
CN101115773A (zh) * 2005-02-07 2008-01-30 格黎卡特生物技术股份公司 结合egfr的抗原结合分子，编码它的载体，及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0975748B1 (en) 1997-04-23 2006-03-29 Universität Zürich Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US7732157B1 (en) * 1999-09-30 2010-06-08 Tumor Biology Investment Group Soluble epidermal growth factor receptor-like proteins and their uses in cancer detection methods
AUPQ841800A0 (en) * 2000-06-28 2000-07-20 Biomolecular Research Institute Limited Truncated egf receptor
CA2450285C (en) * 2001-06-13 2016-08-02 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
JP2003066677A (ja) * 2001-08-24 2003-03-05 Canon Inc カラー画像形成装置及び画像補正制御方法並びに記憶媒体
KR20130065723A (ko) * 2003-06-27 2013-06-19 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
WO2006102901A2 (en) * 2005-03-31 2006-10-05 Pharmexa A/S Immunogenic egfr peptides comprising foreign t cell stimulating epitope
WO2009054917A1 (en) * 2007-10-19 2009-04-30 Amgen Inc. Methods of selecting epidermal growth factor receptor (egfr) binding agents
AU2009301580B2 (en) * 2008-10-06 2015-11-26 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
KR101108642B1 (ko) 2009-09-29 2012-02-09 주식회사 녹십자 표피 성장 인자 수용체에 특이적으로 결합하는 항체
US8962808B2 (en) * 2010-05-05 2015-02-24 The Research Foundation For The State University Of New York EGFR-related polypeptides and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459061A (en) * 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
CN1432063A (zh) * 2000-05-19 2003-07-23 梨树化学株式会社 抗表皮生长因子受体的人源化抗体
CN101115773A (zh) * 2005-02-07 2008-01-30 格黎卡特生物技术股份公司 结合egfr的抗原结合分子，编码它的载体，及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
杨黎青: "《免疫学基础与病原生物学》", 30 April 2007, 中国中医药出版社 *
王进: "《病原生物学与免疫学》", 27 February 2007, 郑州大学出版社 *

Also Published As

Publication number Publication date
CO7160042A2 (es) 2015-01-15
CA2871111A1 (en) 2013-10-03
CN104394879A (zh) 2015-03-04
RU2650770C2 (ru) 2018-04-17
JP2015519875A (ja) 2015-07-16
CA2871111C (en) 2022-06-28
PH12014502360A1 (en) 2015-01-12
EP2832363B1 (en) 2018-09-19
IN2014DN08778A (https=) 2015-05-22
MX2014011597A (es) 2015-03-10
BR112014024192A2 (pt) 2017-07-25
ES2694679T3 (es) 2018-12-26
WO2013147509A1 (ko) 2013-10-03
MY168077A (en) 2018-10-11
KR20140145583A (ko) 2014-12-23
DK2832363T3 (en) 2019-01-07
US20190153117A1 (en) 2019-05-23
JP6209206B2 (ja) 2017-10-04
PH12014502360B1 (en) 2015-01-12
RU2014143032A (ru) 2016-05-20
KR101930019B1 (ko) 2018-12-17
US20170145107A1 (en) 2017-05-25
US20150231220A1 (en) 2015-08-20
EP2832363A4 (en) 2016-03-23
EP2832363A1 (en) 2015-02-04
MX356550B (es) 2018-06-01

Similar Documents

Publication Publication Date Title
US10221246B2 (en) Pan-HER antibody composition
EP3156421B1 (en) Pan-her antibody composition
AU2015295936C1 (en) Anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
KR20120060235A (ko) 특이성 결합 단백질 및 용도
CN110835374A (zh) 抗ccr8×ctla-4双特异性抗体及其应用
KR20150064204A (ko) 인간 유래 항-인간 표피 생장인자 수용체 항체 및 그의 코딩 유전자와 용도
TW202003559A (zh) Ｃ３結合劑及其使用方法
JP2026004416A (ja) Ｈｅｒ２を標的とする抗原結合構築物及び用途
US20190153117A1 (en) Epitopes of epidermal growth factor receptor surface antigen and use thereof
CN109879966B (zh) 基于鼠源cd19抗体的人源化设计及表达验证
KR102239781B1 (ko) Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
WO2025140701A1 (zh) 抗egfr单抗、其双特异性抗体、药物组合物和用途
HK40013803A (en) Epitopes of epidermal growth factor receptor surface antigen and use thereof
KR20260005269A (ko) c-Met를 표적으로 하는 다중 특이성 항체
CN118165107A (zh) 结合tigit的抗体分子

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013803

Country of ref document: HK